Literature DB >> 9816170

Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.

W D Tilley1, G Buchanan, T E Hickey, J M Bentel.   

Abstract

Progression to androgen-independent growth of human prostate cancers may be mediated by alterations in the structure and/or expression of the androgen receptor (AR) gene. To date, mutations in the AR gene have largely been identified in hormone refractory tumors. In this study, single-strand conformational polymorphism analysis and DNA sequencing of the entire AR gene coding region was performed on 25 primary prostate tumors sampled prior to initiation of hormonal (i.e. , androgen ablation) therapy. Base changes leading to amino acid substitutions in the AR were identified in 11 (44%) tumors. The presence of AR amino acid substitutions was associated with decreased immunohistochemical staining for AR in tumor cells and the rapid failure of subsequent hormonal therapies. Single-strand conformational polymorphism analysis of exons 2, 3, and 8 of the X-linked hypoxanthine guanine phosphoribosyl transferase (HPRT) gene in the same samples revealed no bandshifts, suggesting that the high frequency of AR gene mutations detected was not a consequence of generalized genetic instability. These data indicate that AR gene mutations occur commonly in advanced prostate cancers prior to endocrine treatment of disease and may contribute to altered androgen responsiveness of the tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816170

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  70 in total

Review 1.  Prostate cancer: 11. Alternative approaches and the future of treatment.

Authors:  J Trachtenberg; J Crook; I F Tannock
Journal:  CMAJ       Date:  1999-02-23       Impact factor: 8.262

2.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Authors:  Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

Review 3.  Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Authors:  David Lorente; Joaquin Mateo; Zafeiris Zafeiriou; Alan D Smith; Shahneen Sandhu; Roberta Ferraldeschi; Johann S de Bono
Journal:  Nat Rev Urol       Date:  2015-01       Impact factor: 14.432

4.  2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways.

Authors:  Supriya Shah; Janet K Hess-Wilson; Siobhan Webb; Hannah Daly; Sonia Godoy-Tundidor; Jae Kim; Joanne Boldison; Yehia Daaka; Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

5.  A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin.

Authors:  Eleanor F Need; Howard I Scher; Amelia A Peters; Nicole L Moore; Albert Cheong; Charles J Ryan; Gary A Wittert; Villis R Marshall; Wayne D Tilley; Grant Buchanan
Journal:  Endocrinology       Date:  2009-03-12       Impact factor: 4.736

6.  CD147 modulates androgen receptor activity through the Akt/Gsk-3β/β-catenin/AR pathway in prostate cancer cells.

Authors:  Fang Fang; Yingxin Qin; Feng Hao; Qiang Li; Wei Zhang; Chen Zhao; Shuang Chen; Liangzhong Zhao; Liguo Wang; Jianhui Cai
Journal:  Oncol Lett       Date:  2016-06-07       Impact factor: 2.967

7.  Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer.

Authors:  Natalia V Narizhneva; Natalia D Tararova; Petro Ryabokon; Inna Shyshynova; Anatoly Prokvolit; Pavel G Komarov; Andrei A Purmal; Andrei V Gudkov; Katerina V Gurova
Journal:  Cell Cycle       Date:  2009-12-13       Impact factor: 4.534

8.  ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines.

Authors:  Honglin Chen; Stephen J Libertini; Yu Wang; Hsing-Jien Kung; Paramita Ghosh; Maria Mudryj
Journal:  J Biol Chem       Date:  2009-11-28       Impact factor: 5.157

9.  The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth.

Authors:  Kongming Wu; Sanjay Katiyar; Agnes Witkiewicz; Anping Li; Peter McCue; Liang-Nian Song; Lifeng Tian; Ming Jin; Richard G Pestell
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

10.  Prostate cancer epigenetics: a review on gene regulation.

Authors:  Lena Diaw; Karen Woodson; John W Gillespie
Journal:  Gene Regul Syst Bio       Date:  2007-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.